April 2026 Research Update

Studies this month sharpened the picture of who is more likely to develop macrophage activation syndrome (MAS), a serious inflammation complication of adult-onset Still's disease. Across two real-world datasets, higher ferritin (a blood marker of inflammation) and higher systemic disease scores repeatedly showed up as key markers of MAS risk. This month added that these markers can be combined into prediction models that estimate higher-risk profiles, rather than relying on any single lab value alone. [1] [2]

In a large registry-based analysis (737 people), MAS was reported in 11.4% of patients, and the models repeatedly highlighted ferritin, CRP, age, and the systemic score as the most important inputs. When several of these factors were high together, the predicted chance of MAS in the highest-risk profiles was about 33% to 35% in the model outputs. This gives a clearer sense of how risk can rise when multiple warning signals cluster, even though the study does not prove these factors cause MAS. [1]

In a separate single-center cohort (93 people), response rates to anakinra (an IL-1 blocker) and tocilizumab (an IL-6 blocker) were reported as similar, and baseline ferritin and systemic score were again linked to MAS. This study also reported that longer diagnostic delay was tied to worse methotrexate response and lower rates of stopping glucocorticoids, suggesting that delays may be a marker for a harder-to-control disease course in that cohort. Together with the larger registry work, this month made ferritin and systemic scoring stand out as repeated signals to watch in research on MAS prediction. [2]

For patients and caregivers, the main addition this month is a clearer, more consistent set of warning signals that research teams are using to estimate MAS risk: ferritin and a measure of how widespread the disease is (systemic score), often alongside CRP and age. This may matter now mainly as understanding, because these studies describe patterns and prediction models rather than proving that changing a lab value changes outcomes. What remains uncertain is how well any one model works for every clinic and every person, and how these predictions should be used alongside symptoms and doctor assessment. [1] [2]

This month, studies looking at immune system measurements connected Still's disease to recognizable immune activation patterns, and they also showed that infections can come with a distinct immune profile. The overall picture is that some measurable immune signals (in blood cells and plasma proteins) rise together with stronger inflammation, and some of these signals overlap with what is seen in Still's-like illness. These studies do not establish cause and effect, but they make the immune pattern more concrete and measurable. [3] [4]

In a cohort of 277 adults with adult-onset Still's disease, people who developed fungal infections had more organ involvement reported, including an enlarged spleen, lung infiltrates, and pericarditis, compared with those without fungal infection. They also showed higher levels of several immune-activation markers, and ferritin stayed linked to infection even after adjusting for factors like disease activity and steroid exposure. In plain terms, the study describes a subgroup with infections who looked more systemically inflamed and immunologically activated at the time they were assessed. [3]

In a separate European study of adults with unexplained autoinflammation, researchers found higher activation markers across multiple T cell groups and higher acute-phase plasma proteins compared with healthy controls, with some similarities to Still's disease. This matters because it suggests there may be shared immune features across different inflammatory illnesses, even when the exact diagnosis is uncertain. The study does not say these tests should be used for diagnosis yet, but it adds to the idea that Still's-like inflammation can leave a detectable "signature" in blood immune measurements. [4]

For patients, these studies mainly add understanding about what researchers mean by "immune activation" in Still's disease and related inflammatory conditions, and how that activation can look different when certain infections occur. The infection study may matter now as context: it describes that fungal infections, when they happened in this cohort, tended to occur alongside broader organ involvement and higher inflammation markers. What remains uncertain is whether these immune measurements can reliably predict infection or guide monitoring for an individual person, since the studies focused on describing patterns rather than testing a specific care approach. [3] [4]

This month included several case-based reports that highlight how varied adult-onset Still's disease can be and how researchers are searching for underlying biological reasons in selected patients. Taken together, these reports do not change what is known for most people with Still's disease, but they show where uncertainty still exists and what kinds of unusual situations are being documented. They also show the kinds of "deep dive" testing (genetics, immune readouts) researchers may use to explore why one person has a very strong inflammatory response. [5] [6] [7]

One pregnancy case report described adult-onset Still's disease complicated by secondary HLH/MAS, starting with symptoms that looked like a viral upper respiratory illness. The patient improved after high-dose corticosteroids and an IL-1-blocking treatment, but later had a flare that required escalating immune-suppressing treatment. The plain-language message is that Still's disease can sometimes be hard to recognize early, and the course can be unstable even after initial improvement, especially in complex settings like pregnancy. [5]

Another case report focused on a very rare inherited JAK2 gene variant (JAK2 R947Q) in a person with Still's disease, supported by lab and computer modeling that showed stronger cytokine signaling in test systems. Two of the patient's children carried the same variant and had elevated baseline immune activity on blood testing but no disease symptoms reported. This points to the idea that a strong immune "set point" might exist without causing illness on its own, and that extra triggers may be needed, but this remains early research from one family. [7]

A small series described five Still's disease cases and discussed early intervention strategies, but it did not provide specific outcome results in the summary available here. Its contribution this month is mainly that case series are continuing to document how patients present and how clinicians think about timing, rather than adding new comparative evidence about which approach works best. [6]

For patients and caregivers, these reports are best read as examples rather than general expectations, because they describe a small number of people and may not apply to others. They may matter later if the genetic and immune findings are confirmed in more families, since that could help explain why some people have unusually strong inflammatory responses. What remains uncertain is how often rare variants like JAK2 R947Q are involved in Still's disease, and whether such findings can be used in routine care. [5] [7] [6]

One report this month described an international effort to capture how clinicians approach Still's disease and other juvenile rheumatic illnesses in routine practice. The main message was that participation was broad, but awareness and use of local recommendations varied across countries. This kind of work does not test treatments, but it helps explain why care can look different depending on where someone lives and what resources and guidance are locally available. [8]

In the interim survey results, 534 physicians from 66 countries completed 1,193 questionnaires across several pediatric rheumatic diseases, including Still's disease. Respondents included experienced specialists and also younger doctors, and only a few countries reported developing local or national disease-specific recommendations, with variable awareness and adherence. In plain terms, the study documents real variation in shared standards, which can influence how consistently people receive similar evaluations and treatment approaches across settings. [8]

For families, this work mainly adds context rather than new medical findings: it helps explain why different clinics may talk about Still's disease differently or follow different usual routines. It may matter over time if these surveys lead to clearer shared practice strategies and more consistent care pathways, but this paper did not report patient outcomes. What remains uncertain is how much the documented differences in recommendation awareness translate into differences in patient results. [8]